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E M B O L I Z AT I O N

Management of
Type II Endoleaks
Available options for treating the most common type of endoleak after EVAR.
BY RIPAL T. GANDHI, MD, FSVM; YOLANDA BRYCE, MD; SUVRANU GANGULI, MD;
JUSTIN M c WILLIAMS, MD; AND GEOGY VATAKENCHERRY, MD

A

ccording to the National Surgical Quality
Improvement Program, 75% of abdominal
aortic aneurysms are treated with endovascular techniques compared to open repair,1 as
endovascular aneurysm repair (EVAR) is associated with
decreased periprocedural mortality, complications, and
length of hospital stay.2,3 However, some studies have
shown an increased rate of reinterventions in EVAR compared to open repair,4,5 a percentage of which are due to
aneurysm growth secondary to an endoleak. Endoleaks
can occur in up to 20% to 25% of patients after EVAR,6,7
with type II endoleaks being the most common.
Type II endoleaks account for at least 40% of all endoleaks.8 They commonly occur from retrograde collateral
blood flow into the aneurysm sac, typically from a lumbar
artery or the inferior mesenteric artery (IMA).9 Less common sources of type II endoleaks include accessory renal
and median sacral arteries. In patients who require endograft limb extension across the internal iliac artery, this vessel
can also serve as a source of endoleak if it is not adequately
embolized. Endoleaks can lead to enlargement and pressurization of the sac, leading to rupture (which is uncommon). The retrograde collateral blood flow may or may not
result in sac pressurization, as not all of these endoleaks are
associated with aneurysm growth. Type II endoleaks can be
subdivided into type IIa, which has a single causative vessel
involved with “to-and-fro” flow in the aneurysm sac, and
type IIb, in which multiple vessels are involved.
NATURAL HISTORY OF TYPE II ENDOLEAKS
Compared to other endoleaks, type II endoleaks generally
have a benign course, and many spontaneously resolve. In
our experience, type IIa endoleaks have a greater propensity
to spontaneously resolve than type IIb, which tend to be
more complex. In one study, only 19% of type II endoleaks
were associated with aneurysm growth requiring intervention.10 In another study, only 20% required intervention.11

42 ENDOVASCULAR TODAY APRIL 2016 VOL. 15, NO. 4

However, it has been demonstrated that the presence of
a persistent type II endoleak is associated with aneurysm
sac growth, increased reintervention rates, conversion
to open repair, and aneurysm sac rupture.12 A persistent
type II endoleak is described as persisting beyond 6 months.
Predictors of a persistent type II endoleak include a patent
IMA > 2.5 mm in diameter, a lumbar artery > 1.9 mm in
diameter, and more than two lumbar arteries that extend
from the aneurysm sac.13,14
FOLLOW-UP AFTER EVAR AND ENDOLEAK
EVALUATION
After EVAR has been completed, our follow-up protocol
consists of CT angiography (CTA) at 1, 6, and 12 months,
and annually thereafter. Some patients may be followed
every 2 years, especially in the setting of a shrinking sac in
the absence of an endoleak. Patients with renal insufficiency
may be followed with duplex ultrasound and noncontrast
CT. Time-resolved magnetic resonance angiography is used
selectively at our center, sometimes to better determine the
flow dynamics of an endoleak seen on CTA.
It is critical that a proper imaging protocol is utilized for
cross-sectional imaging after EVAR to ensure that endoleaks
are identified. A three-phase scan consisting of a noncontrast scan, an arterial phase, and delayed imaging is essential, and review of previous studies is mandatory. Once an
endoleak is identified, it is critical to determine the endoleak
type in order to guide management. Although cross-sectional imaging can diagnose the presence of an endoleak,
the type of endoleak is not always evident on cross-sectional
imaging alone. In these cases, diagnostic angiography is
required to determine the precise etiology in order to
guide subsequent therapy. Diagnostic angiography should
include an aortogram, as well as selective angiography of the
superior mesenteric artery (SMA) and bilateral internal iliac
arteries. If a type III endoleak is suspected, angiography performed with a pigtail catheter placed within the endograft
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Figure 1. A patient with a type II endoleak via a right lumbar artery (A) and enlarging aortic sac. Angiogram showing a pigtail catheter in the right limb of a bifurcated endograft demonstrates an endoleak being fed by a lumbar artery (arrow) (B).
A 5-F Cobra 2 catheter was placed into the right hypogastric artery, and angiography via a microcatheter placed into the
culprit lumbar artery through the iliolumbar collateral better delineates the endoleak (C). Onyx was administered through
the microcatheter (D). Further embolization was carried out until there was complete filling of the endoleak sac, as well as
the feeding artery, with embolic agent (E). Final angiogram after embolization shows no further endoleak (F).

may be useful. Another useful technique is placement of an
occlusion balloon above the pigtail catheter in the graft to
increase the sensitivity for type III endoleak assessment. The
latter strategy is also useful in identifying a type Ib endoleak
by deploying a compliant balloon in the iliac limb and performing power injection angiography at the distal seal site. If
a significant amount of contrast or radiation dose has been
utilized during these diagnostic procedures, it is not unreasonable to stage the therapy with the treatment procedure
performed on a later date once the endoleak type and etiology are determined.
It is important to note that the presence of one type
of endoleak does not exclude a second type of endoleak.
Endoleaks are often complex, and successful treatment
of one endoleak does not preclude later development of
another. Therefore, longitudinal follow-up of these patients
is mandatory. Furthermore, filling of the IMA or lumbar
arteries on cross-sectional imaging does not always repre-

sent a type II endoleak; we have seen many patients who
have a subtle type Ia endoleak with resultant antegrade flow
in these vessels (inflow from the proximal attachment zone
and outflow from the lumbar/IMA), which is best appreciated on aortography.
TREATMENT APPROACH
At Miami Cardiac and Vascular Institute, type II endoleaks are only treated if there is evidence of aneurysm growth
(generally > 5 mm). There are multiple approaches to the
management of these endoleaks, including transarterial,
translumbar, transcaval, and surgical approaches.
Transarterial Embolization
The transarterial and translumbar approaches are most
commonly used to address these endoleaks, and there are
conflicting data on which technique is more effective. The
transarterial approach is our preferred first-line therapy
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to manage these endoleaks. It is important to stress that
persistent type II endoleaks associated with aneurysm
enlargement typically behave like arteriovenous malformations, with multiple ingress and egress vessels. Treatment
of the nidus, or endoleak sac, is critical for an effective and
durable result. The challenge lies in the ability to advance
a microcatheter in a retrograde manner from the SMA
(via the arc of Riolan or marginal artery of Drummond)
to the IMA or from the internal iliac artery (via the iliolumbar artery) to the culprit lumbar artery. It is essential
to advance the microcatheter to the aneurysm sac; however, these collateral pathways can be long and extremely
tortuous, which can be difficult and sometimes impossible to navigate. Complete obliteration of the endoleak
nidus with elimination of all inflow and outflow vessels is
required to prevent recurrence. Proximal embolization is
not recommended, as the type II endoleak will recur by
recruiting additional aortic branch vessels, possibly making
the treatment even more complex.
Stable access in the SMA or internal iliac artery is the
first important step in performing transarterial embolization. A 5-F Cobra catheter or reverse-curve catheter (ie, Sos,
Simmons) are our initial “go-to” catheters. In the setting
of significant tortuosity and an inability to achieve stable
access with these catheters, steerable guiding sheaths such
as the Destino (Oscor Inc.) or Morph (BioCardia, Inc.) catheter, or the Magellan robotic catheter (Hansen Medical, Inc.)
can be valuable. A 150-cm-long microcatheter with a 0.021inch inner diameter or smaller is recommended. We typically use a dimethylsulfoxide-compatible microcatheter such
as Echelon or Rebar (Medtronic) to allow treatment with
the Onyx liquid embolic system (Medtronic). Although the
Progreat microcatheter (Terumo Interventional Systems)
is not validated as dimethylsulfoxide compatible, we have
not encountered any problem injecting Onyx through it.
We typically use coils and/or Onyx to treat the majority of
these endoleaks. One potential benefit of Onyx is the ability
to advance beyond the site of delivery and disperse through
the endoleak nidus/sac to fill the ingress and egress vessels
(Figure 1). Because Onyx is radiopaque, it can be closely
followed under fluoroscopic guidance, and injection may
be stopped if there is inadvertent nontarget delivery of the
embolic agent. The MVP microvascular plug (Medtronic)
is a newer device that can be delivered via a microcatheter.
An advantage of this device is the presence of polytetrafluoroethylene, which results in immediate flow occlusion with
minimal artifact on posttreatment CTA. We typically do
not use cyanoacrylate glue, but this is a reasonable embolic
alternative. Onyx, glue, and coils can make subsequent
endoleak evaluation difficult due to significant streak artifact on CT imaging. In these situations, one can consider
magnetic resonance angiography to look for a persistent
44 ENDOVASCULAR TODAY APRIL 2016 VOL. 15, NO. 4

leak where the artifact from these embolic agents can be
minimized. It is possible that new liquid embolic agents may
allow better results in terms of imaging.
Translumbar Embolization
If transarterial embolization is either not feasible or
unsuccessful in resolving the endoleak, direct translumbar
percutaneous access into the aneurysm sac can be performed. CTA is closely evaluated to determine an optimal
site for entry such that the access needle will target the
endoleak cavity. Our technique involves placing the patient
in the prone position and placing a sheath needle into the
aneurysm sac using either anatomic landmarks (ie, vertebral
body, radiopaque markers on the endograft, calcification)
or XperGuide software (Philips Healthcare) with cone beam
CT. Another approach is to gain access into the aneurysm
sac under CT guidance and subsequently move the patient
to a fluoroscopy suite. Care is taken to avoid puncturing
the endograft, as this may result in a type III endoleak. We
tend to favor a left translumbar approach, if possible, to
avoid the course of the inferior vena cava (IVC). However,
some endoleaks may necessitate a right-sided transcaval
approach. Incidentally, intravasated embolic material into
the IVC may result in pulmonary embolism.
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Figure 2. A patient with persistent type II endoleak despite previous embolization via a transarterial route. Translumbar direct
sac puncture of the aortic sac is performed utilizing XperGuide software in conjunction with cone beam CT and fluoroscopic guidance (A). A 20-cm sheath needle is advanced into the endoleak sac until pulsatile arterial blood flow is noted (B, C). A contrast injection (saccogram) is performed through an access needle (D). Note that coils are from the previous embolization procedure. Because
ingress and egress vessels are not easily visualized, thrombin was injected into the sac (E). Pressure measurement via the sheath
needle demonstrates a decrease in pressure from 81/73 to 50/48 mm Hg after embolization, with loss of pulsatility (F).

Once the aneurysm sac is accessed and pulsatile blood is
seen, baseline pressure measurements are obtained, which
are subsequently compared to postembolization pressures.
A diagnostic angiogram or “saccogram” is then obtained
via the sheath needle to delineate the endoleak cavity and
inflow and outflow vessels. A microcatheter is typically
introduced coaxially to negotiate the nidus, and an attempt
is made to catheterize every inflow and outflow vessel. If
the latter vessels can be catheterized, coil embolization is
performed. The endoleak sac is finally embolized with coils,
Onyx, and/or thrombin. If it is not technically possible to
select all of the vessels contributing to the endoleak, Onyx
is administered under real-time fluoroscopy until there is
embolization of the sac as well as the vessels. Thrombin
46 ENDOVASCULAR TODAY APRIL 2016 VOL. 15, NO. 4

injection into the sac is another effective alternative, but
the inability to visualize and control the thrombin injection
makes it less ideal. The benefit of thrombin is the absence of
artifact on cross-sectional imaging, which allows for better
detection of residual endoleak, but it might lead to a higher
rate of recanalization. A final intrasac pressure measurement
is obtained after embolization (Figure 2).
Results using this technique have been published, and
the authors found it to be a useful bailout technique for
persistent endoleaks after EVAR; however, endoleak recurrence was relatively high (50%) at a median follow-up of 39
months, and reintervention was deemed necessary in 33%
of cases. Repeat endoleaks following embolization were
associated with the use of dual-antiplatelet therapy.15
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Transcatheter Transcaval Approach
The transcatheter transcaval approach to the aneurysm sac is uncommonly used, but it does have some
utility, especially in the setting of a posterior endoleak
in close proximity to the IVC, which is otherwise difficult to access. This technique is an alternative to the
translumbar or transcaval approach. A prerequisite for
utilizing this approach is CT evidence of close proximity or adhesion of the caval wall to the aneurysm sac.
Furthermore, there must be sufficient space between
the wall of the aneurysm abutting the IVC and the
endograft to allow for entry into the endoleak cavity
without puncturing the graft. The common femoral
vein or internal jugular vein may be utilized for access.

F

A 10-F, 40-cm reinforced sheath, identical to that used
for transjugular intrahepatic portosystemic shunt
procedures, is then placed. Using a combination of
landmarks from preprocedural imaging, fluoroscopic
imaging, and/or intravascular ultrasound, the sheath is
wedged against the posterior caval wall. The presence
of aortic wall calcification may limit intravascular ultrasound evaluation; however, it can serve as an important fluoroscopic target. A small amount of contrast is
injected to confirm that the sheath is against the caval
wall. The endoleak is then accessed with a Colapinto
needle (Cook Medical), and a 5-F cannula with catheter is advanced into the endoleak sac. Once arterial
blood flow is seen, intrasac pressure measurements are
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obtained, followed by contrast administration (saccogram). Embolization is then performed similarly to
translumbar embolization. A cavagram is obtained at
the conclusion of embolization.
Potential complications related to this technique
include pulmonary embolism from nontarget delivery
of embolic material, retroperitoneal hemorrhage, and
aortocaval fistula. If there is adhesion between the caval
wall and aorta, retroperitoneal hemorrhage is unlikely to
occur. According to a study published by Mansueto et al,
these complications were not encountered.16
Surgical Treatment
Laparoscopic, robotic, and open surgical ligation
of mesenteric, lumbar, and other offending arteries
are options for patients in whom the endovascular
approach fails, with persistent endoleak with aneurysm
growth. Other surgical options include plication of the
aneurysm and graft explantation.
RESULTS OF PREVENTION OF TYPE II ENDOLEAK
In an attempt to prevent subsequent type II endoleaks,
one institution employed a protocol of embolizing all
IMAs if they were successfully visualized and accessed
prior to EVAR. They noted decreased rates in type II
endoleak incidence, aneurysm sac enlargement, and
reintervention rates at 24 months.17 Another institution
performed intraprocedural abdominal aortic aneurysm
sac embolization, which was shown to result in freedom
from type II endoleak at 6 months and type II endoleak–
related reinterventions, but without demonstration of
differences in aneurysm sac size.18 Given the time constraints, lack of robust data, and the fact that the majority of type II endoleaks regress, aggressive preventive
techniques have not been practical or adopted at our
institution and are not routinely employed. That being
said, we occasionally preemptively embolize the IMA or
lumbar arteries if they are unusually large and/or if there
is an “empty sac” with minimal luminal thrombus. Newer
technology, such as the Nellix endograft (Endologix, Inc.),
which fills the aneurysm sac with a polymer-filled endobag, may decrease the incidence of type II endoleaks and
reintervention rates.
CONCLUSION
In summary, type II endoleaks after EVAR are a common finding but are often of no clinical significance.
However, in the setting of a persistent endoleak with
concomitant aneurysm growth, secondary interventions are indicated. Further investigation is required to
determine the most effective approach and optimal
embolic agent(s) to manage this complication. n
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